Skip to main
RNAC
RNAC logo

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics Inc. demonstrates a robust potential for growth, as evidenced by anticipated positive outcomes from its Phase 3 trial for Descartes-08, building on the impressive results of its Phase 2 trials. The company projects substantial market penetration, aiming for approximately 30% in the U.S. and 20% across the EU5 by 2037, which reflects strong commercial viability for its innovative treatments. Additionally, the favorable tolerability and response durability of Descartes-08, along with a solid financial position, suggest a promising outlook for ongoing and future clinical developments.

Bears say

Cartesian Therapeutics Inc. reported a net loss of $0.40 per share for 4Q24 and a projected net loss of $2.75 per share for the full year 2025, indicating ongoing financial challenges. The efficacy of their lead product, Vyvgart, has shown variable clinical benefits, with the optimal therapeutic effects waning rapidly, which could hinder patient satisfaction and treatment adherence. Additionally, the company faces significant operational risks, including potential delays in clinical trials and concerns regarding the safety of their treatments, which may contribute to long-term dilution risk for shareholders.

RNAC has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Buy based on their latest research and market trends.

According to 1 analysts, RNAC has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.